We are inspired by the challenge to help protect public health in an ever-changing world.

Medicago is a pioneer and global leader in developing and producing plant-based vaccines and therapeutics.

Our story starts in Canada where we have a long track record of research and development. The Medicago team has used their ingenuity and passion to create a disruptive technology that seeks to help improve public health across the globe. No easy feat in the context of a global pandemic.

Improving public health

Through the development of our proprietary Proficia® technology, we use the power of plants to help solve some of the most difficult challenges facing us today and in the future. Our plant-based technology, Proficia, allows us to synthesize a virus code, using plants as bioreactors to produce a non-infectious particle that mimics the target virus.

Health is in our Nature

Beyond using nature to help solve the world’s emergent public health issues, nature is a big part of who we are. But what is our nature? Who is Medicago, and what sets us apart? Let’s take a look at some of our core values:

  1. Innovation – we challenge conventional methods to provide health solutions
  2. Integrity – we are committed to safety and quality, and our goal is to never compromise this principle
  3. Collaboration – we strive to bring together the brightest minds in the industry
  4. Adaptability – we are positioned to rapidly adapt to and address emerging health challenges globally
  5. Ownership – we value each role within Medicago as every one of us makes a difference

Pandemic Response

Efficiency and versatility are two of our greatest qualities. The technology and infrastructure, which we have in place today, allows us to provide a solution to help address the current COVID-19 pandemic as well as future pandemics— and fast. For example, in 2009, Medicago was able to produce a research grade H1N1 vaccine candidate in just 19 days.

For more information about how Medicago is leading the distinctive plant-based technology approach to develop vaccines and therapeutic proteins, visit our Virus-like particles page.